Physiomics plc (PYC) ORD GBP0.004
Physiomics Plc is engaged in the provision of outsourced systems and computational biology services to pharmaceutical companies. The Company is focused on the development of Virtual Tumour Clinical, to directly predict optimal regimens for human clinical trials; Cardiac tox prediction service, to predict unwanted toxic side effects of drug candidates in the drug discovery process, and Drug combinations database, for researchers and clinicians to access literature data on pre-clinical and clinical regimens and their effects. Its services include Target Validation, Mechanism of Action Studies, Lead Selection, Clinical Pharmacokinetic/Pharmacodynamics (PK/PD), EASYAP/Cardiac Toxicity Service, Virtual Tumour Preclinical and Virtual Tumour Clinical. It offers a services and technology for predicting cardiac toxicity. It also focuses on offering offer Model Based Drug Development (MBDD) services, which include Population PKPD analysis of clinical data and Back-translational analysis.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.